{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:39:33Z","timestamp":1793342373358,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004930","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000}}],"reference-count":13,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1004930","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:44:36Z","timestamp":1769798676000},"page":"e1004930","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8379-1497","authenticated-orcid":true,"given":"Giulia","family":"Notini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":true,"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":true,"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"8","key":"pmed.1004930.ref001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"C Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"pmed.1004930.ref002","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","author":"SM Tolaney","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"pmed.1004930.ref003","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"J Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"pmed.1004930.ref004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"SM Tolaney","year":"2025","journal-title":"JCO"},{"key":"pmed.1004930.ref005","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","author":"S Loibl","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"pmed.1004930.ref006","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"N Harbeck","year":"2026","journal-title":"Ann Oncol"},{"issue":"11","key":"pmed.1004930.ref007","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/jnci\/djaf220","article-title":"Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer","volume":"117","author":"P Tarantino","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"pmed.1004930.ref008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-025-07818-z","article-title":"Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer","volume":"214","author":"S Nezirevic","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"pmed.1004930.ref009","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"I Valle","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"pmed.1004930.ref010","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"A D\u2019Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"pmed.1004930.ref011","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70001","article-title":"Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis","volume":"55","author":"M Perachino","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"pmed.1004930.ref012","article-title":"Innovative antibody therapeutic development in China compared with the USA and Europe","author":"S Crescioli","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"pmed.1004930.ref013","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation","volume":"15","author":"Y Shi","year":"2020","journal-title":"J Thorac Oncol"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004930","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:43:52Z","timestamp":1770230632000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004930","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}